Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01525095 · ClinicalTrials.gov registry record
Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT)
A clinical trial of Candidemia, sponsored by T2 Biosystems.
- Completed
- Registry status
- 700
- Enrollment target
- 5
- Study locations
NCT01525095 is a study of Candidemia that has completed, run by T2 Biosystems. The registered enrollment target is 700 participants, above the 327-participant average among 8 other Candidemia trials with a reported enrollment target (114% higher). The trial reports 5 study locations across 5 states.
The verdict
NCT01525095, a study of Candidemia, has completed, sponsored by T2 Biosystems.
- COMPLETED
- Registry status
- 700 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to assure the uniform collection, handling, storage and transport of patient whole blood specimens and associated information to support validation of the T2 Candida Assay.
Conditions Studied
Study Locations (5)
Alabama
- University of Alabama at Birmingham - Birmingham
California
- University of California San Francisco - San Francisco
Kentucky
- University of Kentucky - Lexington
Michigan
- Henry Ford Hospital - Detroit
Texas
- University of Houston College of Pharmacy - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2012-01 |
| Est. Completion | 2014-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01525095
The ClinicalTrials.gov registry entry for NCT01525095 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 700 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 327-participant average among 8 other Candidemia trials with a reported enrollment target (114% higher). The listed sponsor is T2 Biosystems, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Candidemia appearing as the primary indexed condition, and to 0 interventions.
NCT01525095 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Alabama, California, Kentucky.
Frequently Asked Questions
What is clinical trial NCT01525095 about?
NCT01525095 is a clinical study titled "Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT)". The purpose of this study is to assure the uniform collection, handling, storage and transport of patient whole blood specimens and associated information to support validation of the T2 Candida Assay.
What is the current status of trial NCT01525095?
This trial is currently completed. The enrollment target is 700 participants. The study started on 2012-01. Estimated completion is 2014-03.
What conditions does trial NCT01525095 study?
This clinical trial studies the following conditions: Candidemia.
Who is sponsoring clinical trial NCT01525095?
This trial is sponsored by T2 Biosystems, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01525095 being conducted?
This trial has 5 study locations across Alabama, California, Kentucky, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Candidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
RECRUITING · Phase 3
-
Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia
RECRUITING · Phase 2
-
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
ACTIVE NOT RECRUITING · Phase 3
-
Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
COMPLETED · Phase 1
-
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
COMPLETED · Phase 3
-
Study of Micafungin in Patients With Invasive Candidiasis or Candidemia
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.